2023 - Research.com Medicine in Japan Leader Award
His primary areas of study are Internal medicine, Endocrinology, Endothelium, Cardiology and Nitric oxide. His Internal medicine research integrates issues from Fasudil and Rho-associated protein kinase. His work is dedicated to discovering how Endocrinology, Pulmonary hypertension are connected with Hypoxia and other disciplines.
His Endothelium research is multidisciplinary, incorporating elements of Vasodilation, Biochemistry, Bradykinin, Pharmacology and Endothelium-derived hyperpolarizing factor. His Angina, Ejection fraction, Chest pain and Ischemia study, which is part of a larger body of work in Cardiology, is frequently linked to Vasospasm, bridging the gap between disciplines. His Nitric oxide study which covers Mesenteric arteries that intersects with Dihydrobiopterin and Biopterin.
His scientific interests lie mostly in Internal medicine, Cardiology, Endocrinology, Heart failure and In patient. Internal medicine is a component of his Nitric oxide, Myocardial infarction, Endothelium, Ejection fraction and Pulmonary hypertension studies. The Endothelium study combines topics in areas such as Endothelium-derived hyperpolarizing factor and Vasodilation.
Hiroaki Shimokawa usually deals with Cardiology and limits it to topics linked to In vivo and Pharmacology. In his research on the topic of Endocrinology, Pathogenesis is strongly related with Rho-associated protein kinase. His Heart failure research is multidisciplinary, relying on both Intensive care medicine and Hazard ratio.
Hiroaki Shimokawa mainly focuses on Internal medicine, Cardiology, Heart failure, In patient and Pulmonary hypertension. His Internal medicine study frequently draws connections between related disciplines such as Endocrinology. His work on Vasospastic angina, Chronic thromboembolic pulmonary hypertension, Artery and Angina as part of general Cardiology research is frequently linked to Chart, thereby connecting diverse disciplines of science.
His Heart failure study incorporates themes from Diabetes mellitus, Proportional hazards model, Atrial fibrillation and Intensive care medicine. The study incorporates disciplines such as Hypoxia, Lung, Pulmonary artery, Hemodynamics and Pharmacology in addition to Pulmonary hypertension. In his study, Rivaroxaban is strongly linked to Stroke, which falls under the umbrella field of Myocardial infarction.
Hiroaki Shimokawa mainly investigates Internal medicine, Cardiology, Heart failure, Hazard ratio and Endocrinology. His is doing research in Myocardial infarction, Pulmonary hypertension, Angina, Coronary artery disease and Stroke, both of which are found in Internal medicine. His work on Ejection fraction, Artery and Coronary arteries as part of general Cardiology study is frequently linked to In patient, bridging the gap between disciplines.
His Hazard ratio research includes themes of Placebo, Prospective cohort study, Randomized controlled trial and Survival analysis. As part of his studies on Endocrinology, Hiroaki Shimokawa often connects relevant subjects like Proinflammatory cytokine. His studies deal with areas such as Microcirculation and Vascular smooth muscle as well as Endothelium.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M Ridker;Brendan M. Everett;Tom Thuren;Jean G. MacFadyen.
The New England Journal of Medicine (2017)
Heart failure: preventing disease and death worldwide.
Piotr P. Ponikowski;Stefan D. Anker;Khalid F. AlHabib;Martin R. Cowie.
Esc Heart Failure (2014)
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M Ridker;Jean G MacFadyen;Tom Thuren;Brendan M Everett.
The Lancet (2017)
Endothelial dysfunction and vascular disease
P. M. Vanhoutte;H. Shimokawa;E. H. C. Tang;M. Feletou.
Acta Physiologica (2009)
The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation.
Hiroaki Shimokawa;Hiroshi Yasutake;Koji Fujii;M. Owada.
Journal of Cardiovascular Pharmacology (1996)
International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology
Jelena Rima Ghadri;Ilan Shor Wittstein;Abhiram Prasad;Scott Sharkey.
European Heart Journal (2018)
Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice
Tetsuya Matoba;Hiroaki Shimokawa;Mikio Nakashima;Yoji Hirakawa.
Journal of Clinical Investigation (2000)
Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris.
Yoku Kikuchi;Kenta Ito;Yoshitaka Ito;Takashi Shiroto.
Japanese Circulation Journal-english Edition (2010)
Extracorporeal cardiac shock wave therapy improves left ventricular remodeling after acute myocardial infarction in pigs
Toyokazu Uwatoku;Kenta Ito;Kohtaro Abe;Keiji Oi.
Coronary Artery Disease (2007)
Cardiac shock wave therapy ameliorates left ventricular remodeling after myocardial ischemia-reperfusion injury in pigs in vivo.
Yoshitaka Ito;Kenta Ito;Takashi Shiroto;Ryuji Tsuburaya.
Coronary Artery Disease (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: